Suzhou Alphamab Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2008-11-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.alphamab.com
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06747416
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Phase 3
Recruiting
- Conditions
- Hemophilia A Without InhibitorHemophilia B Without Inhibitor
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT06569108
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06547775
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
Phase 3
Recruiting
- Conditions
- Hemophilia B With InhibitorHemophilia A With Inhibitor
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT06312475
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Phase 2
Recruiting
- Conditions
- Knee Arthroplasty, Total
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06180889
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
Phase 2
Completed
- Conditions
- Hemophilia
- Interventions
- Biological: KN057 dose ⅡBiological: KN057 dose ⅢBiological: KN057 doseⅠ
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05421429
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳stitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate Effects of KN056 in Healthy Participants
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: KN056 (0.1mg)Drug: KN056 (0.3mg)Drug: KN056 (1.0mg)Drug: KN056 (3.0mg)Drug: KN056 (6.0mg)Drug: KN056 (12.0mg)Drug: KN056 (18.0mg)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT05385575
- Locations
- 🇳🇿
Alexandra Cole, Christchurch, New Zealand
© Copyright 2025. All Rights Reserved by MedPath